Epigenetic histone modifications involved in profibrotic gene regulation by 12/15-lipoxygenase and its oxidized lipid products in diabetic nephropathy

Antioxidants and Redox Signaling

Volumn 24, Issue 7, 2016, Pages 361-375

  Yuan, Hang ^a,b   Reddy, Marpadga A ^a   Deshpande, Supriya ^a   Jia, Ye ^a,c   Park, Jung Tak ^a,d   Lanting, Linda L ^a   Jin, Wen ^a   Kato, Mitsuo ^a   Xu, Zhong Gao ^b   Das, Sadhan ^a   Natarajan, Rama ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

^c THE SECOND HOSPITAL OF JILIN UNIVERSITY   (China)

^d Yonsei University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONATE 12 LIPOXYGENASE; ARACHIDONATE 15 LIPOXYGENASE; HISTONE H3; HYDROXYICOSATETRAENOIC ACID; SET 7 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; 12-15-LIPOXYGENASE; HISTONE; HISTONE LYSINE METHYLTRANSFERASE; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; EPIGENETICS; GENE CONTROL; GENE EXPRESSION; GENE SILENCING; HISTONE MODIFICATION; LIPID OXIDATION; LOSS OF FUNCTION MUTATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; RAT; TRANSCRIPTION INITIATION; ANIMAL; CHROMATIN IMMUNOPRECIPITATION; DISEASE MODEL; DRUG EFFECTS; EXPERIMENTAL DIABETES MELLITUS; FIBROSIS; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; HIGH THROUGHPUT SEQUENCING; KNOCKOUT MOUSE; LIPID METABOLISM; MESANGIUM CELL; METABOLISM; OXIDATION REDUCTION REACTION; PATHOLOGY; PATHOPHYSIOLOGY;

ANIMALS; ARACHIDONATE 12-LIPOXYGENASE; ARACHIDONATE 15-LIPOXYGENASE; CHROMATIN IMMUNOPRECIPITATION; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; DISEASE MODELS, ANIMAL; EPIGENESIS, GENETIC; FIBROSIS; GENE EXPRESSION REGULATION; GENE SILENCING; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HISTONE-LYSINE N-METHYLTRANSFERASE; HISTONES; HYDROXYEICOSATETRAENOIC ACIDS; LIPID METABOLISM; MESANGIAL CELLS; MICE; MICE, KNOCKOUT; OXIDATION-REDUCTION; PROMOTER REGIONS, GENETIC; RATS; TRANSFORMING GROWTH FACTOR BETA;

EID: 84959237489     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2015.6372     Document Type: Article

References (63)

1. Advani A, Huang Q, Thai K, Advani SL, White KE, Kelly DJ, Yuen DA, Connelly KA, Marsden PA, and Gilbert RE. Long-term administration of the histone deacetylase inhibitor vorinostat attenuates renal injury in experimental diabetes through an endothelial nitric oxide synthasedependent mechanism. Am J Pathol 178: 2205-2214, 2011
2. Antonipillai I, Nadler J, Vu EJ, Bughi S, Natarajan R, andHorton R. A 12-lipoxygenase product, 12-hydroxyeicosatetraenoic acid, is increased in diabetics with incipient, and early renal disease. J Clin Endocrinol Metab 81: 1940-1945, 1996
3. Brasacchio D, Okabe J, Tikellis C, Balcerczyk A, George P, Baker EK, Calkin AC, Brownlee M, Cooper ME, and El-Osta A. Hyperglycemia induces a dynamic cooperativity of histone methylase, and demethylase enzymes associated with gene-activating epigenetic marks that coexist on the lysine tail. Diabetes 58: 1229-1236, 2009
4. Brownlee M. Biochemistry, and molecular cell biology of diabetic complications. Nature 414: 813-820, 2001
5. Chen J, Guo Y, Zeng W, Huang L, Pang Q, Nie L, Mu J, Yuan F, and Feng B. ER stress triggers MCP-1 expression through SET7/9-induced histone methylation in the kidneys of db/db mice. Am J Physiol Renal Physiol 306: F916-F925, 2014
6. Chua S, Jr., Li Y, Liu SM, Liu R, Chan KT, Martino J, Zheng Z, Susztak K, D?Agati VD, and Gharavi AG. A susceptibility gene for kidney disease in an obese mouse model of type II diabetes maps to chromosome 8. Kidney Int 78: 453-462, 2010
7. Cyrus T, Pratico D, Zhao L, Witztum JL, Rader DJ, Rokach J, FitzGerald GA, and Funk CD. Absence of 12/15-lipoxygenase expression decreases lipid peroxidation, and atherogenesis in apolipoprotein e-deficient mice. Circulation 103: 2277-2282, 2001
8. Dobrian AD, Lieb DC, Cole BK, Taylor-Fishwick DA, Chakrabarti SK, and Nadler JL. Functional, and pathological roles of the 12-and 15-lipoxygenases. Prog Lipid Res 50: 115-131, 2011
9. El-Osta A, Brasacchio D, Yao D, Pocai A, Jones PL, Roeder RG, Cooper ME, and Brownlee M. Transient high glucose causes persistent epigenetic changes, and altered gene expression during subsequent normoglycemia. J Exp Med 205: 2409-2417, 2008
10. Funk CD. The molecular biology of mammalian lipoxygenases, and the quest for eicosanoid functions using lipoxygenase-deficient mice. Biochim Biophys Acta 1304: 65-84, 1996
11. Guo QY, Miao LN, Li B, Ma FZ, Liu N, Cai L, and Xu ZG. Role of 12-lipoxygenase in decreasing P-cadherin, and increasing angiotensin II type 1 receptor expression accord-ing to glomerular size in type 2 diabetic rats. Am J Physiol Endocrinol Metab 300: E708-E716, 2011
12. Jirtle RL, and Skinner MK. Environmental epigenomics, and disease susceptibility. Nat Rev Genet 8: 253-262, 2007
13. Jones CA, Krolewski AS, Rogus J, Xue JL, Collins A, and Warram JH. Epidemic of end-stage renal disease in people with diabetes in the United States population: do we know the cause?. Kidney Int 67: 1684-1691, 2005
14. Jones PA. Functions of DNA methylation: islands, start sites, gene bodies, and beyond. Nat Rev Genet 13: 484-492, 2012
15. Kang SW, Adler SG, Nast CC, LaPage J, Gu JL, Nadler JL, and Natarajan R. 12-Lipoxygenase is increased in glucosestimulated mesangial cells, and in experimental diabetic nephropathy. Kidney Int 59: 1354-1362, 2001
16. Kanwar YS, Sun L, Xie P, Liu FY, and Chen S. A glimpse of various pathogenetic mechanisms of diabetic nephropathy. Annu Rev Pathol 6: 395-423, 2011
17. Kato M, Dang V, Wang M, Park JT, Deshpande S, Kadam S, Mardiros A, Zhan Y, Oettgen P, Putta S, Yuan H, Lanting L, and Natarajan R. TGF-beta induces acetylation of chromatin, and of Ets-1 to alleviate repression of miR-192 in diabetic nephropathy. Sci Signal 6: ra43, 2013
18. Kato M, and Natarajan R. Diabetic nephropathy-emerging epigenetic mechanisms. Nat Rev Nephrol 10: 517-530, 2014
19. Kato M, Yuan H, Xu ZG, Lanting L, Li SL, Wang M, Hu MC, Reddy MA, and Natarajan R. Role of the Akt/FoxO3a pathway in TGF-beta1-mediated mesangial cell dysfunction: a novel mechanism related to diabetic kidney disease. J Am Soc Nephrol 17: 3325-3335, 2006
20. Keating ST, and El-Osta A. Glycemic memories, and the epigenetic component of diabetic nephropathy. Curr Diab Rep 13: 574-581, 2013
21. Kim YS, Reddy MA, Lanting L, Adler SG, and Natarajan R. Differential behavior of mesangial cells derived from 12/15-lipoxygenase knockout mice relative to control mice. Kidney Int 64: 1702-1714, 2003
22. Kim YS, Xu ZG, Reddy MA, Li SL, Lanting L, Sharma K, Adler SG, and Natarajan R. Novel interactions between TGF-{beta}1 actions, and the 12/15-lipoxygenase pathway in mesangial cells. J Am Soc Nephrol 16: 352-362, 2005
23. Komers R, Mar D, Denisenko O, Xu B, Oyama TT, and Bomsztyk K. Epigenetic changes in renal genes dysregulated in mouse, and rat models of type 1 diabetes. Lab Invest 93: 543-552, 2013
24. Kouzarides T. Chromatin modifications, and their function. Cell 128: 693-705, 2007
25. Kutz SM, Higgins CE, Samarakoon R, Higgins SP, Allen RR, Qi L, and Higgins PJ. TGF-beta 1-induced PAI-1 expression is E box/USF-dependent, and requires EGFR signaling. Exp Cell Res 312: 1093-1105, 2006
26. Li SL, Reddy MA, Cai Q, Meng L, Yuan H, Lanting L, and Natarajan R. Enhanced proatherogenic responses in macrophages, and vascular smooth muscle cells derived from diabetic db/db mice. Diabetes 55: 2611-2619, 2006
27. Li Y, Reddy MA, Miao F, Shanmugam N, Yee JK, Hawkins D, Ren B, and Natarajan R. Role of the histone H3 lysine 4 methyltransferase, SET7/9, in the regulation of NF-kappaBdependent inflammatory genes. Relevance to diabetes, and inflammation. J Biol Chem 283: 26771-26781, 2008
28. Loeffler I, and Wolf G. Transforming growth factor-beta, and the progression of renal disease. Nephrol Dial Transplant 29 Suppl 1: i37-i45, 2014
29. Miyazono K, ten Dijke P, and Heldin CH. TGF-beta signaling by Smad proteins. Adv Immunol 75: 115-157, 2000
30. Murea M, Park JK, Sharma S, Kato H, Gruenwald A, Niranjan T, Si H, Thomas DB, Pullman JM, Melamed ML, and Susztak K. Expression of Notch pathway proteins correlates with albuminuria, glomerulosclerosis, and renal function. Kidney Int 78: 514-522, 2010
31. Natarajan R, and Nadler JL. Lipoxygenases, and lipid signaling in vascular cells in diabetes. Front Biosci 8: s783-s795, 2003
32. Natarajan R, and Nadler JL. Lipid inflammatory mediators in diabetic vascular disease. Arterioscler Thromb Vasc Biol 24: 1542-1548, 2004
33. Natarajan R, and Reddy MA. HETEs/EETs in renal glomerular, and epithelial cell functions. Curr Opin Pharmacol 3: 198-203, 2003
34. Nishioka K, Chuikov S, Sarma K, Erdjument-Bromage H, Allis CD, Tempst P, and Reinberg D. Set9, a novel histone H3 methyltransferase that facilitates transcription by precluding histone tail modifications required for heterochromatin formation. Genes Dev 16: 479-489, 2002
35. Noh H, Oh EY, Seo JY, Yu MR, Kim YO, Ha H, and Lee HB. Histone deacetylase-2 is a key regulator of diabetesand transforming growth factor-beta1-induced renal injury. Am J Physiol Renal Physiol 297: F729-F739, 2009
36. Obrosova IG, Stavniichuk R, Drel VR, Shevalye H, Vareniuk I, Nadler JL, and Schmidt RE. Different roles of 12/15-lipoxygenase in diabetic large, and small fiber peripheral, and autonomic neuropathies. Am J Pathol 177: 1436-1447, 2010
37. Okabe J, Orlowski C, Balcerczyk A, Tikellis C, Thomas MC, Cooper ME, and El-Osta A. Distinguishing hyperglycemic changes by set7 in vascular endothelial cells. Circ Res 110: 1067-1076, 2012
38. Parthasarathy S, and Santanam N. Mechanisms of oxidation, antioxidants, and atherosclerosis. Curr Opin Lipidol 5: 371-375, 1994
39. Putta S, Lanting L, Sun G, Lawson G, Kato M, and Natarajan R. Inhibiting microRNA-192 ameliorates renal fibrosis in diabetic nephropathy. J Am Soc Nephrol 23: 458-469, 2012
40. Reddy MA, Adler SG, Kim YS, Lanting L, Rossi J, Kang SW, Nadler JL, Shahed A, and Natarajan R. Interaction of MAPK, and 12-lipoxygenase pathways in growth, and matrix protein expression in mesangial cells. Am J Physiol Renal Physiol 283: F985-F994, 2002
41. Reddy MA, Kim YS, Lanting L, and Natarajan R. Reduced growth factor responses in vascular smooth muscle cells derived from 12/15-lipoxygenase-deficient mice. Hypertension 41: 1294-1300, 2003
42. Reddy MA, and Natarajan R. Epigenetics in diabetic kidney disease. J Am Soc Nephrol 22: 2182-2185, 2011
43. Reddy MA, Sumanth P, Lanting L, Yuan H, Wang M, Mar D, Alpers CE, Bomsztyk K, and Natarajan R. Losartan reverses permissive epigenetic changes in renal glomeruli of diabetic db/db mice. Kidney Int 85: 362-373, 2014
44. Reddy MA, Tak Park J, and Natarajan R. Epigenetic modifications in the pathogenesis of diabetic nephropathy. Semin Nephrol 33: 341-353, 2013
45. Reddy MA, Thimmalapura PR, Lanting L, Nadler JL, Fatima S, and Natarajan R. The oxidized lipid, and lipoxygenase product 12(S)-hydroxyeicosatetraenoic acid induces hypertrophy, and fibronectin transcription in vascular smooth muscle cells via p38 MAPK, and cAMP response element-binding protein activation. Mediation of angiotensin II effects. J Biol Chem 277: 9920-9928, 2002
46. Reidy K, Kang HM, Hostetter T, and Susztak K. Molecular mechanisms of diabetic kidney disease. J Clin Invest 124: 2333-2340, 2014
47. Reilly KB, Srinivasan S, Hatley ME, Patricia MK, Lannigan J, Bolick DT, Vandenhoff G, Pei H, Natarajan R, Nadler JL, and Hedrick CC. 12/15-Lipoxygenase activity mediates inflammatory monocyte/endothelial interactions, and atherosclerosis in vivo. J Biol Chem 279: 9440-9450, 2004
48. Ruggenenti P, Cravedi P, and Remuzzi G. The RAAS in the pathogenesis, and treatment of diabetic nephropathy. Nat Rev Nephrol 6: 319-330, 2010
49. Sanchez AP, and Sharma K. Transcription factors in the pathogenesis of diabetic nephropathy. Expert Rev Mol Med 11: e13, 2009
50. Sharma K, Jin Y, Guo J, and Ziyadeh FN. Neutralization of TGF-beta by anti-TGF-beta antibody attenuates kidney hypertrophy, and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice. Diabetes 45: 522-530, 1996
51. Shevalye H, Lupachyk S, Watcho P, Stavniichuk R, Khazim K, Abboud HE, and Obrosova IG. Prediabetic nephropathy as an early consequence of the high-calorie/high-fat diet: relation to oxidative stress. Endocrinology 153: 1152-1161, 2012
52. Sun G, Reddy MA, Yuan H, Lanting L, Kato M, and Natarajan R. Epigenetic histone methylation modulates fibrotic gene expression. J Am Soc Nephrol 21: 2069-2080, 2010
53. Susztak K. Understanding the epigenetic syntax for the genetic alphabet in the kidney. J Am Soc Nephrol 25: 10-17, 2014
54. Suzuki H, Kayama Y, Sakamoto M, Iuchi H, Shimizu I, Yoshino T, Katoh D, Nagoshi T, Tojo K, Minamino T, Yoshimura M, and Utsunomiya K. Arachidonate 12/15-lipoxygenase-induced inflammation, and oxidative stress are involved in the development of diabetic cardiomyopathy. Diabetes 64: 618-630, 2015
55. Wang D, Zhou J, Liu X, Lu D, Shen C, Du Y, Wei FZ, Song B, Lu X, Yu Y, Wang L, Zhao Y, Wang H, Yang Y, Akiyama Y, Zhang H, and Zhu WG. Methylation of SUV39H1 by SET7/9 results in heterochromatin relaxation, and genome instability. Proc Natl Acad Sci U S A 110: 5516-5521, 2013
56. Wang H, Cao R, Xia L, Erdjument-Bromage H, Borchers C, Tempst P, and Zhang Y. Purification, and functional characterization of a histone H3-lysine 4-specific methyltransferase. Mol Cell 8: 1207-1217, 2001
57. Xu ZG, Li SL, Lanting L, Kim YS, Shanmugam N, Reddy MA, and Natarajan R. Relationship between 12/15-lipoxygenase, and COX-2 in mesangial cells: potential role in diabetic nephropathy. Kidney Int 69: 512-519, 2006
58. Xu ZG, Miao LN, Cui YC, Jia Y, Yuan H, and Wu M. Angiotensin II type 1 receptor expression is increased via 12-lipoxygenase in high glucose-stimulated glomerular cells, and type 2 diabetic glomeruli. Nephrol Dial Transplant 24: 1744-1752, 2009
59. Xu ZG, Yuan H, Lanting L, Li SL, Wang M, Shanmugam N, Kato M, Adler SG, Reddy MA, and Natarajan R. Products of 12/15-lipoxygenase upregulate the angiotensin II receptor. J Am Soc Nephrol 19: 559-569, 2008
60. Yamamoto S. Mammalian lipoxygenases: molecular structures, and functions. Biochim Biophys Acta 1128: 117-131, 1992
61. Yuan H, Lanting L, Xu ZG, Li SL, Swiderski P, Putta S, Jonnalagadda M, Kato M, and Natarajan R. Effects of cholesterol-tagged small interfering RNAs targeting 12/15-lipoxygenase on parameters of diabetic nephropathy in a mouse model of type 1 diabetes. Am J Physiol Renal Physiol 295: F605-F617, 2008
62. Yuan H, Reddy MA, Sun G, Lanting L, Wang M, Kato M, and Natarajan R. Involvement of p300/CBP, and epigenetic histone acetylation in TGF-beta1-mediated gene transcription in mesangial cells. Am J Physiol Renal Physiol 304: F601-F613, 2013
63. Ziyadeh FN, and Sharma K. Overview: combating diabetic nephropathy. J Am Soc Nephrol 14: 1355-1357, 2003